IGC Pharma annual ebitda
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma EBITDA Growth & History (IGC)
IGC Pharma's calculated EBITDA was −$7.4M for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | −$7.4M | — | — |
| 2025 · Mar 31 | 2025-03-31 | −$6.8M | $2.3M | — |
| 2024 | 2024-03-31 | −$9.2M | $1.8M | — |
| 2023 | 2023-03-31 | −$10.9M | $3.9M | — |
| 2022 | 2022-03-31 | −$14.8M | −$6.5M | — |
| 2021 | 2021-03-31 | −$8.2M | −$1.5M | — |
| 2020 | 2020-03-31 | −$6.7M | −$2.1M | — |
| 2019 | 2019-03-31 | −$4.6M | −$2.8M | — |
| 2018 | 2018-03-31 | −$1.8M | −$111,961 | — |
| 2017 | 2017-03-31 | −$1.7M | $518,930 | — |
| 2016 | 2016-03-31 | −$2.2M | $1.4M | — |
| 2015 | 2015-03-31 | −$3.6M | −$1.7M | — |
| 2014 | 2014-03-31 | −$1.8M | −$5,740 | — |
| 2013 | 2013-03-31 | −$1.8M | $4.7M | — |
| 2012 | 2012-03-31 | −$6.5M | $8.6M | — |
| 2011 | 2011-03-31 | −$15.1M | — | — |
IGC Pharma quarterly ebitda
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | −$2.7M | −$964,000 | — |
| Q1 2026 · Mar 31 | 2026-03-31 | −$2.4M | −$1.1M | — |
| Q4 2025 | 2025-12-31 | −$1.6M | $103,000 | — |
| Q2 2026 · Sep 30 | 2025-09-30 | −$2.8M | −$1.2M | — |
| Q1 2026 · Jun 30 | 2025-06-30 | −$1.8M | $470,000 | — |
| Q4 2025 | 2025-03-31 | −$1.3M | $747,000 | — |
| Q3 2025 | 2024-12-31 | −$1.7M | $1.1M | — |
| Q2 2025 | 2024-09-30 | −$1.6M | $718,000 | — |
| Q1 2025 | 2024-06-30 | −$2.2M | −$250,000 | — |
| Q4 2024 | 2024-03-31 | −$2.0M | $1.8M | — |
| Q3 2024 | 2023-12-31 | −$2.8M | −$732,000 | — |
| Q2 2024 | 2023-09-30 | −$2.3M | −$15,000 | — |
| Q1 2024 | 2023-06-30 | −$2.0M | $656,000 | — |
| Q4 2023 | 2023-03-31 | −$3.9M | $2.5M | — |
| Q3 2023 | 2022-12-31 | −$2.1M | $113,000 | — |
| Q2 2023 | 2022-09-30 | −$2.3M | $1.9M | — |
| Q1 2023 | 2022-06-30 | −$2.6M | −$603,000 | — |
| Q4 2022 | 2022-03-31 | −$6.3M | −$3.7M | — |
| Q3 2022 | 2021-12-31 | −$2.2M | −$20,000 | — |
| Q2 2022 | 2021-09-30 | −$4.2M | −$2.6M | — |
| Q1 2022 | 2021-06-30 | −$2.0M | −$183,000 | — |
| Q4 2021 | 2021-03-31 | −$2.6M | −$257,000 | — |
| Q3 2021 | 2020-12-31 | −$2.2M | −$545,000 | — |
| Q2 2021 | 2020-09-30 | −$1.6M | −$308,000 | — |
| Q1 2021 | 2020-06-30 | −$1.9M | −$416,000 | — |
| Q4 2020 | 2020-03-31 | −$2.4M | −$685,000 | — |
| Q3 2020 | 2019-12-31 | −$1.7M | −$90,000 | — |
| Q2 2020 | 2019-09-30 | −$1.3M | −$419,000 | — |
| Q1 2020 | 2019-06-30 | −$1.4M | −$942,000 | — |
| Q4 2019 | 2019-03-31 | −$1.7M | −$1.0M | — |
| Q3 2019 | 2018-12-31 | −$1.6M | −$1.1M | — |
| Q2 2019 | 2018-09-30 | −$841,000 | −$582,000 | — |
| Q1 2019 | 2018-06-30 | −$496,000 | −$105,695 | — |
| Q4 2018 | 2018-03-31 | −$652,695 | $142,411 | — |
| Q3 2018 | 2017-12-31 | −$468,000 | −$277,991 | — |
| Q2 2018 | 2017-09-30 | −$259,000 | $192,791 | — |
| Q1 2018 | 2017-06-30 | −$390,305 | −$169,172 | — |
| Q4 2017 | 2017-03-31 | −$795,106 | $689,134 | — |
| Q3 2017 | 2016-12-31 | −$190,009 | $41,991 | — |
| Q2 2017 | 2016-09-30 | −$451,791 | −$92,425 | — |
| Q1 2017 | 2016-06-30 | −$221,133 | −$119,770 | — |
| Q4 2016 | 2016-03-31 | −$1.5M | $119,849 | — |
| Q3 2016 | 2015-12-31 | −$232,000 | $113,421 | — |
| Q2 2016 | 2015-09-30 | −$359,366 | $250,759 | — |
| Q1 2016 | 2015-06-30 | −$101,363 | $899,747 | — |
| Q4 2015 | 2015-03-31 | −$1.6M | −$331,328 | — |
| Q3 2015 | 2014-12-31 | −$345,421 | −$199,113 | — |
| Q2 2015 | 2014-09-30 | −$610,125 | −$325,266 | — |
| Q1 2015 | 2014-06-30 | −$1.0M | −$889,650 | — |
| Q4 2014 | 2014-03-31 | −$1.3M | $917,840 | — |
| Q3 2014 | 2013-12-31 | −$146,308 | −$736,474 | — |
| Q2 2014 | 2013-09-30 | −$284,859 | −$186,185 | — |
| Q1 2014 | 2013-06-30 | −$111,460 | −$921 | — |
| Q4 2013 | 2013-03-31 | −$2.2M | $2.0M | — |
| Q3 2013 | 2012-12-31 | $590,166 | $1.6M | — |
| Q2 2013 | 2012-09-30 | −$98,674 | $545,103 | — |
| Q1 2013 | 2012-06-30 | −$110,539 | $536,664 | — |
| Q4 2012 | 2012-03-31 | −$4.2M | $8.7M | — |
| Q3 2012 | 2011-12-31 | −$1.0M | $21,258 | — |
| Q2 2012 | 2011-09-30 | −$643,777 | $51,103 | — |
| Q1 2012 | 2011-06-30 | −$647,203 | −$211,338 | — |
| Q4 2011 | 2011-03-31 | −$12.9M | — | — |
| Q3 2011 | 2010-12-31 | −$1.0M | — | — |
| Q2 2011 | 2010-09-30 | −$694,880 | — | — |
| Q1 2011 | 2010-06-30 | −$435,865 | — | — |
IGC Pharma ebitda trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's ebitda increased from −$15.1M to −$7.4M, a change of $7.7M. The latest reported quarter, Q2 2026 · Jun 30, shows −$2.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗